A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: Direct in vivo comparison with the 111In-labelled analogue

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 7, 2010, Pages 1356-1367

  Tolmachev, Vladimir ^a,b   Velikyan, Irina ^b,c   Sandström, Mattias ^d   Orlova, Anna ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c BIACORE AB   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

68Ga; Affibody molecule; HER2; Molecular imaging; Tumour targeting

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ABY 002 GA 68; ABY 002 IN 111; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GALLIUM 68; INDIUM 111; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; AFFIBODY (ZHER2-342)2; GALLIUM; HYBRID PROTEIN; INDIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; GASTROINTESTINAL TRACT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LUNG; MALE; MOUSE; MUSCLE CELL; NONHUMAN; OVARY CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PROSTATE CARCINOMA; PROTEIN BINDING; PROTEIN EXPRESSION; RADIOACTIVITY; RADIOCHEMISTRY; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; DIAGNOSTIC USE; INJECTION; METABOLISM; PROCEDURES; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; FEMALE; GALLIUM RADIOISOTOPES; HUMANS; INDIUM RADIOISOTOPES; INJECTIONS; ISOTOPE LABELING; MICE; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS;

EID: 77954955636     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1367-7     Document Type: Article

References (50)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
2. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006;7:505-16.
3. Carlsson J. EGFR-family expression and implications for targeted radionuclide therapy. In: Stigbrand T, Carlsson J, Adams G, editors. Targeted radionuclide tumor therapy: biological aspects. New York: Springer; 2008. p. 25-58.
4. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45.
5. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, et al. Tumor markers in breast cancer-European Group on Tumor Markers recommendations. Tumour Biol 2005;26:281-93.
6. Verri E, Guglielmini P, Puntoni M, Perdelli L, Papadia A, Lorenzi P, et al. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study. Oncology 2005;68:154-61.
7. Nakamura H, Kawasaki N, Taguchi M, Kabasawa K. Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis. Cancer 2005;103:1865-73.
8. Morote J, de Torres I, Caceres C, Vallejo C, Schwartz S Jr, Reventos J. Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer. Int J Cancer 1999;84:421-5.
9. Shi Y, Brands FH, Chatterjee S, Feng AC, Groshen S, Schewe J, et al. Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol 2001;166:1514-9.
10. Carles J, Lloreta J, Salido M, Font A, Suarez M, Baena V, et al. Her-2/neu expression in prostate cancer: a dynamic process? Clin Cancer Res 2004;10:4742-5.
11. Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des 2008;14:2999-3019.
12. Dijkers EC, de Vries EG, Kosterink JG, Brouwers AH, Lub-de Hooge MN. Immunoscintigraphy as potential tool in the clinical evaluation of HER2/neu targeted therapy. Curr Pharm Des 2008;14:3348-62.
13. Nygren PA. Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J 2008;275:2668-76.
14. Orlova A, Feldwisch J, Abrahmsén L, Tolmachev V. Update: affibody molecules for molecular imaging and therapy for cancer. Cancer Biother Radiopharm 2007;22:573-84.
15. Mume E, Orlova A, Larsson B, Nilsson AS, Nilsson FY, Sjöberg S, et al. Evaluation of ((4-hydroxyphenyl) ethyl) maleimide for site-specific radiobromination of anti-HER2 affibody. Bioconjug Chem 2005;16:1547-55.
16. Kramer-Marek G, Kiesewetter DO, Martiniova L, Jagoda E, Lee SB, Capala J. [18F]FBEM-Z (HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging 2008;35:1008-18.
17. Cheng Z, De Jesus OP, Namavari M, De A, Levi J, Webster JM, et al. Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules. J Nucl Med 2008;49:804-13.
18. Wållberg H, Ahlgren S, Widström C, Orlova A. Evaluation of the radiocobalt-labeled [MMA-DOTA-Cys61]-Z HER2:2395 (-Cys) affibody molecule for targeting of HER2-expressing tumors. Mol Imaging Biol 2010;12:54-62.
19. Orlova A, Wållberg H, Stone-Elander S, Tolmachev V. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzu-mab in a murine xenograft model. J Nucl Med 2009;50:417-25.
20. Kramer-Marek G, Kiesewetter DO, Capala J. Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18) F-labeled affibody molecules. J Nucl Med 2009;50:1131-9.
21. Rösch F, Knapp FF. Radionuclide generators. In: Vértes A, Nagy S, Klencsár Z, Rösch F, editors. Handbook of nuclear chemistry. Dordrecht: Kluwer Academic; 2003;4. p. 81-118.
22. Velikyan I, Beyer GJ, Långström B. Microwave-supported preparation of (68) Ga bioconjugates with high specific radioactivity. Bioconjug Chem 2004;15:554-60.
23. Breeman WA, de Jong M, de Blois E, Bernard BF, Konijnenberg M, Krenning EP. Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging 2005;32:478-85.
24. Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA, et al. Processing of generator-produced 68Ga for medical application. J Nucl Med 2007;48:1741-8.
25. Meyer GJ, Mäcke H, Schuhmacher J, Knapp WH, Hofmann M. 68Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging 2004;31:1097-104.
26. Decristoforo C, Hernandez Gonzalez I, Carlsen J, Rupprich M, Huisman M, Virgolini I, et al. 68Ga-and 111In-labelled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging 2008;35:1507-15.
27. Maecke HR, André JP. 68Ga-PET radiopharmacy: a generator-based alternative to 18F-radiopharmacy. Ernst Schering Res Found Workshop 2007;62:215-42.
28. Orlova A, Tolmachev V, Pehrson R, Lindborg M, Tran T, Sandström M, et al. Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res 2007;67:2178-86.
29. Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34:982-93.
30. Froidevaux S, Calame-Christe M, Schuhmacher J, Tanner H, Saffrich R, Henze M, et al. A gallium-labeled DOTA-alpha-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med 2004;45:116-23.
31. Zhang H, Schuhmacher J, Waser B, Wild D, Eisenhut M, Reubi JC, et al. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur J Nucl Med Mol Imaging 2007;34:1198-208.
32. Persson M, Tolmachev V, Andersson K, Gedda L, Sandström M, Carlsson J. [(177) Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. Eur J Nucl Med Mol Imaging 2005;32:1457-62.
33. Wållberg H, Orlova A. Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers. Cancer Biother Radiopharm 2008;23:435-42.
34. Orlova A, Wållberg H, Tolmachev V. Optimisation of specific radioactivity of Affibody molecule enables in vivo discrimination between high and low HER2 expression. Eur J Nucl Med Mol Imaging 2008;35 Suppl 2: S187.
35. Arora P, Oas TG, Myers JK. Fastand faster: a designed variant of the B-domain of protein A folds in 3 microsec. Protein Sci 2004;13:847-53.
36. Ahlgren S, Wållberg H, Tran TA, Widström C, Hjertman M, Abrahmsén L, et al. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. J Nucl Med 2009;50:781-9.
37. Wei L, Zhang X, Gallazzi F, Miao Y, Jin X, Brechbiel MW, et al. Melanoma imaging using (111) In-, (86) Y-and (68) Ga-labeled CHX-A"-Re (Arg11) CCMSH. Nucl Med Biol 2009;36:345-54.
38. de Jong M, Bakker WH, Krenning EP, Breeman WA, van der Pluijm ME, Bernard BF, et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0, d-Phe1, Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997;24:368-71.
39. Heppeler A, Froidevaux S, Mäcke H, Jermann E, Béhé M, Powell P, et al. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur J 1999;5:1974-81.
40. Froidevaux S, Eberle AN, Christe M, Sumanovski L, Heppeler A, Schmitt JS, et al. Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model. Int J Cancer 2002;98:930-7.
41. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 2004;22:701-6.
42. Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res 2005;65:1471-8.
43. Garmestani K, Milenic DE, Plascjak PS, Brechbiel MW. A new and convenient method for purification of 86Y using a Sr (II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin. Nucl Med Biol 2002;29:599-606.
44. Dijkers EC, Kosterink JG, Rademaker AP, Perk LR, van Dongen GA, Bart J, et al. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med 2009;50:974-81.
45. Webster JM, Zhang R, Gambhir SS, Cheng Z, Syud FA. Engineered two-helix small proteins for molecular recognition. Chembiochem 2009;10:1293-6.
46. Ren G, Zhang R, Liu Z, Webster JM, Miao Z, Gambhir SS, et al. A 2-helix small protein labeled with 68Ga for PET imaging of HER2 expression. J Nucl Med 2009;50(9):1492-9.
47. Melis M, Bijster M, de Visser M, Konijnenberg MW, de Swart J, Rolleman EJ, et al. Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours. Eur J Nucl Med Mol Imaging 2009 Jul. 8. [Epub ahead of print].
48. Bernard BF, Krenning EP, Breeman WA, Rolleman EJ, Bakker WH, Visser TJ, et al. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 1997;38(12):1929-33.
49. Vegt E, van Eerd JE, Eek A, Oyen WJ, Wetzels JF, de Jong M, et al. Reducing renal uptake of radiolabeled peptides using albumin fragments. J Nucl Med 2008;49(9):1506-11.
50. Béhé M, Kluge G, Becker W, Gotthardt M, Behr TM. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J Nucl Med 2005;46(6):1012-5.